Navigation Links
Screening for HPV persistence and cervical cancer risk
Date:9/6/2011

Women over the age of thirty who test positive for HPV (Human Papillomavirus) should be re-tested two years later as part of cervical cancer screening, according to a study published online TK in the Journal of the National Cancer Institute.

HPV infection is the main cause of cervical cancer, although most women infected with HPV do not have cervical pathology and most HPV infections in women under the age of 25 go away. Screening is recommended for women over age thirty, and the type of HPV strain to screen for is important, since only some are associated with cervical cancer risk. Furthermore, only persistently detectable infections seem to be associated with cervical cancer risk. However, few long-term studies have been done on the persistence of these infections and cervical cancer risk.

To determine the association between persistent HPV infections and cervical cancer risk in women over the age of thirty, Hui-Chi Chen, PhD, of the Genomics Research Center of Academia Sinica in Taipei, Taiwan, and colleagues, followed a cohort of 11,923 women aged 30󈞭 over a period of 16 years. The women underwent baseline exams that included HPV DNA testing and cytological tests, and the tests were repeated two years later. Incidence of cervical cancer was determined from cancer registries and death registries. In total, 6,666 women participated in both baseline and second visits, whereas the other 3,456 patients underwent only the first exam.

The researchers found that the 16-year risk of cervical cancer was 6.2% for women infected with any carcinogenic strains of the virus. Among women who were persistently infected with carcinogenic HPVs over the 2-year testing period, cervical cancer risk was 12.4%, whereas the risk was only 0.14% for women who repeatedly tested HPV negative. Since the duration of infection, rather than one-time infection, predicts cervical cancer risk, the researchers said it would not be useful to repeat HPV testing more frequently than every two years for HPV-positive women.

The authors write, "Our findings suggest that, if upon testing an HPV infection is found, re-testing 2 years later would provide useful guidance as to the duration of infection and its risk." Furthermore, they say, "The accumulated evidence suggests that it is time to include HPV testing in cancer screening programs for the general population."

The researchers add that genotyping may improve HPV testing since certain carcinogenic HPV strainsnamely HPV16 and HPV58were associated with a higher risk of cervical cancer than others.

In an accompanying editorial, Kevin A. Ault, MD, of the Department of Gynecology and Obstetrics at Emory University School of Medicine notes that "persistent HPV infection is an intermediate step in the development of cervical cancer." He notes the study has several strengths, including long duration of follow-up, a large sample size, and linkage to the national cancer registry. He also adds that the study shows that women with negative HPV tests have a greatly reduced risk of developing cervical disease.


'/>"/>

Contact: Zack Rathner
jncimedia@oxfordjournals.org
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Troubled Teens Spotted in Routine School Screenings: Study
2. Single flexible sigmoidoscopy screening associated with reduced colorectal cancer
3. Annual cervical cancer screening persists, despite recommended guidelines
4. New prostate cancer screening test shows promise for diagnosis
5. New high-speed 3-D imaging system holds potential for improved cancer screening
6. Drop in Breast Cancer Death Rates May Not Be Linked to Screening Rates
7. Study examines screening for pancreatic cancer in high-risk populations
8. Sudden cardiac death in young athletes: Study suggests many ECG screenings are inaccurate
9. Updating family history of cancer associated with need for earlier or more intense cancer screening
10. Changes in family history of cancer can impact screening recommendations
11. Lack of clarity about HPV vaccine and the need for cervical cancer screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, ... ... a standard process in many scientific laboratories. The assembly protocols involve many repetitive ... is well suited for automation, which enables the high-throughput needed, and results in ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the University of Pennsylvania ... have made a $10 million gift to establish the Ken Moelis and Julie ... pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as ... they either don’t have access to a health care facility or a pharmacy within 60 ... of the United States or for many who are faced with health or personal issues ...
(Date:3/28/2017)... ... ... The Thyroid Secret is a specialized 9-part documentary series ... recently launched on March 1, and Dr. Wentz discussed varied benefits and aspects ... Wentz is a licensed pharmacist and a foremost thyroid specialist. After being diagnosed ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the leading provider ... a free, public-facing tool for analyzing the costs of various drug regimens in ... information to patients, providers, insurers and pharmaceutical companies about the estimated costs of ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology: